Overview

Remifentanil/Sufentanil for CABG+/-AVR Evaluated by Recovery, Cognitive Function, Haemodynamics and Biochemical Markers.

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
To evaluate the effect on cognitive function, recovery, cardioprotection and haemodynamics of standard Remifentanil anaesthesia to standard Sufentanil anaesthesia in patients undergoing coronary artery bypass with or without aortic valve replacement.
Phase:
Phase 4
Details
Lead Sponsor:
Aarhus University Hospital
Treatments:
Analgesics, Opioid
Anesthetics
Remifentanil
Sufentanil